SYDNEY, AUSTRALIA – Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep” or “the Company”) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with avelumab*, a human anti-PD-L1 antibody, in patients with advanced solid malignancies.
“We are delighted to have the opportunity to collaborate with Merck KGaA, Darmstadt, Germany, and Pfizer on this Phase I clinical trial that will evaluate the clinical benefits of combining our immune stimulator, eftilagimod alpha, with avelumab, a PD-L1 blocking mechanism of action. We feel that this new collaboration, with these industry leaders, further supports our hypothesis that there is a potentially meaningful therapeutic benefit in combining eftilagimod alpha with a checkpoint inhibitor in the treatment of cancer. We look forward to the initiation of this clinical trial, planned for later this year, and the prospects of further clinical investigations,” said Marc Voigt, CEO of Immutep.
For further information please download PDF attached:
Download this document